Intravitreal Aflibercept for Diabetic Macular Edema

A head-to-head comparison was performed between vascular endothelial growth factor blockade and laser for treatment of diabetic macular edema (DME).Two similarly designed, double-masked, randomized, phase 3 trials, VISTA(DME) and VIVID(DME).We included 872 patients (eyes) with type 1 or 2 diabetes mellitus who presented with DME with central involvement.Eyes received either intravitreal aflibercept injection (IAI) 2 mg every 4 weeks (2q4), IAI 2...